抗GM-CSF抗体奥替利单抗对比托法替布或安慰剂治疗活动性类风湿关节炎且对传统合成或生物改善病情抗风湿药应答不足的患者:两项3期随机试验(contRAst 1和contRAst 2)
两项3期双盲随机对照试验纳入对甲氨蝶呤(contRAst 1)或传统合成/生物改善病情抗风湿药(contRAst 2)应答不足的活动性类风湿关节炎患者,比较皮下奥替利单抗(90/150 mg每周一次)与安慰剂(第12周终点)或口服托法替布(5 mg每日两次,第24周终点)的疗效与安全性。奥替利单抗在ACR20、CDAI低疾病活动度和HAQ-DI方面优于安慰剂,但多项终点上托法替布获益一致优于奥替利单抗,安全性各组相似。
要点
- 奥替利单抗90 mg和150 mg组第12周ACR20应答率在两项试验中均显著高于安慰剂组。
- 与安慰剂相比,奥替利单抗增加CDAI低疾病活动度应答者比例并降低HAQ-DI评分,但contRAst 1中150 mg组的CDAI低疾病活动度未达显著。
- 多项终点上托法替布的获益一致大于奥替利单抗,各组安全性结局相似。
核心结论
- 奥替利单抗在ACR20、CDAI低疾病活动度和HAQ-DI方面优于安慰剂并改善症状,且安全性可接受,但劣于托法替布。
研究设计与样本
- 两项3期双盲随机对照试验contRAst 1和contRAst 2,分别纳入对甲氨蝶呤或传统合成/生物改善病情抗风湿药应答不足的患者,患者均接受背景传统合成改善病情抗风湿药。
- 患者接受皮下奥替利单抗90/150 mg每周一次,通过检验层级与安慰剂比较第12周终点(此后安慰剂组患者转为活性干预),或与口服托法替布5 mg每日两次比较第24周终点。
- 主要终点为第12周达到美国风湿病学会应答≥20%(ACR20)的患者比例。
- 意向治疗人群分别为1537例(contRAst 1)和1625例(contRAst 2)。
主要发现
- contRAst 1中ACR20应答者比例:奥替利单抗90 mg组54.7%(p=0.0023)、150 mg组50.9%(p=0.0362) vs 安慰剂组41.7%。
- contRAst 2中ACR20应答者比例:奥替利单抗90 mg组54.9%(p<0.0001)、150 mg组54.5%(p<0.0001) vs 安慰剂组32.5%。
- 两项试验中,与安慰剂相比,奥替利单抗增加CDAI低疾病活动度应答者比例并降低HAQ-DI评分,但contRAst 1中奥替利单抗150 mg组的CDAI低疾病活动度未达显著。
- 多项终点上托法替布的获益一致大于奥替利单抗,各治疗组安全性结局相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the efficacy and safety of otilimab, an antigranulocyte-macrophage colony-stimulating factor antibody, in patients with active rheumatoid arthritis. METHODS: Two phase 3, double-blind randomised controlled trials including patients with inadequate responses to methotrexate (contRAst 1) or conventional synthetic/biologic disease-modifying antirheumatic drugs (cs/bDMARDs; contRAst 2). Patients received background csDMARDs. Through a testing hierarchy, subcutaneous otilimab (90/150 mg once weekly) was compared with placebo for week 12 endpoints (after which, patients receiving placebo switched to active interventions) or oral tofacitinib (5 mg two times per day) for week 24 endpoints. PRIMARY ENDPOINT: proportion of patients achieving an American College of Rheumatology response ≥20% (ACR20) at week 12. RESULTS: The intention-to-treat populations comprised 1537 (contRAst 1) and 1625 (contRAst 2) patients. PRIMARY ENDPOINT: proportions of ACR20 responders were statistically significantly greater with otilimab 90 mg and 150 mg vs placebo in contRAst 1 (54.7% (p=0.0023) and 50.9% (p=0.0362) vs 41.7%) and contRAst 2 (54.9% (p<0.0001) and 54.5% (p<0.0001) vs 32.5%). Secondary endpoints: in both trials, compared with placebo, otilimab increased the proportion of Clinical Disease Activity Index (CDAI) low disease activity (LDA) responders (not significant for otilimab 150 mg in contRAst 1), and reduced Health Assessment Questionnaire-Disability Index (HAQ-DI) scores. Benefits with tofacitinib were consistently greater than with otilimab across multiple endpoints. Safety outcomes were similar across treatment groups. CONCLUSIONS: Although otilimab demonstrated superiority to placebo in ACR20, CDAI LDA and HAQ-DI, improved symptoms, and had an acceptable safety profile, it was inferior to tofacitinib. TRIAL REGISTRATION NUMBERS: NCT03980483, NCT03970837.
引用
- Fleischmann RM, van der Heijde D, Strand V, et al. Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2). Ann Rheum Dis. 2023. PMID: 37699654. doi:10.1136/ard-2023-224482
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。